Performance Returns to Growth Trajectory丨CMS (867.HK, 8A8.SG) 2025 Annual Performance Report in One Picture

CMS: New Drug for Renal Anaemia Desidustat Tablets Approved in China

Desidustat Tablets are a noveloral HIF-PHI, approved for treating anaemia in non-dialysis adult CKD patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia. The China Phase III clinical trial of the Product has demonstrated positive results: the study met its primary efficacy endpoint. Extension study results demonstrated that the Product can maintain Hb level within the target range over the long term with acceptable safety, while significantly reducing hepcidin levels and ameliorating iron metabolism disorders. The Product will strengthen the Group’s layout in the field of nephrology and synergize with the marketed innovative drug Velphoro for CKD hyperphosphatemia in terms of expert resources and channel networks.   China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been […]